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Research article  
Pancreatogenic type 3C diabetes  
 Anca Pantea-Stoian1,2*, Georgiana Ditu2, Mircea Diculescu1, Mircea Manuc1, Andra 
Iulia Suceveanu3, Dana Manuc1, Camelia Diaconu1, Adrian Paul Suceveanu3, Cornelia 
Nitipir1, Razvan Hainarosie1, Catalina Poiana1, Cristian Serafinceanu1,2  
 
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania 
2N.C. Paulescu National Institute of Diabetes, Nutrition and Metabolic Disease, Bucharest, Romania 
3Emergency County Clinical Hospital of Constanta, Romania  
   
Abstract Background. The relationship between chronic pancreatitis and diabetes is well 
established. This form of diabetes is secondary to exocrine pancreatic disorder and is 
known as diabetes mellitus type 3c (T3cDM). 
Materials and Methods. In this retrospective study we included 261 patients, 59 
patients being diagnosed with chronic pancreatitis and secondary diabetes mellitus, and 
admitted in the Fundeni Clinical Institute, 2nd Department of Gastroenterology or N.C. 
Paulescu Institute/ Carol Davila University of Medicine and Pharmacy. 
Results and Discussions. Patients were 22.2% women and 77.8% men, with an 
average age of 56.8 years and 53.4 years respectively. 63% came from urban areas. The 
mean duration of chronic pancreatitis was six years. Non-diabetic patients were 
compared with patients who were previously diagnosed with T3cDM and who had been 
analyzed for body mass index (BMI). Imaging investigations were also performed to 
confirm pseudotumors or pancreatic tumours. Patients already considered non-diabetic 
had basal blood glucose values and were mostly overweight and obese. In this context, 
insulin resistance cannot be excluded for this group of patients. 
Conclusions. T3cDM is a new pathological entity that needs to be explored more 
deeply, and that should benefit from both a diagnostic stratification and treatment.   
  
 
Keywords  diabetes mellitus, chronic pancreatitis, risk factors, pancreatic surgery, alcohol abuse, 
smoking, obesity  
  
 
 
 
 
 
 
 
 
 
 
Highlights ✓ T3cDM is a new pathological entity that needs to be explored more deeply to lead to 
improved diagnosis and therapeutic stability.  
✓ More studies are needed on this topic due to the fact that the exact mechanisms of onset 
of T3cDM are not fully known.     
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Introduction 
Secondary diabetes is a relatively common entity in 
chronic pancreatitis, so named pancreatogenic diabetes 
or types 3c diabetes. It is mostly due to changes in 
insulin secretion by pancreatic beta cells at islands. As a 
rule, the insulin secretory deficit is complete, following 
a long evolution of chronic pancreatitis. Beta cell 
secretory function decreases relatively parallel to the 
decline in pancreatic exocrine function (1). Most 
patients with chronic pancreatitis have an exocrine 
pancreatic insufficiency closely correlated with 
endocrine function. The prevalence of alteration of 
glucose tolerance is 40-70%, half of these patients 
having insulin-susceptible diabetes. Endocrine failure is 
progressive and occurs on average ten years after the 
diagnosis of chronic pancreatitis. The severity of 
endocrine dysfunction is dependent on the degree of 
pancreatic parenchymal involvement, but is also 
affected by the level of alcohol consumption. In insulin-
dependent patients who develop secondary diabetes 
mellitus of chronic pancreatitis, beta cell function is 
somewhat preserved, and glucoregulation is better, 
compared to patients with type I diabetes (2, 3).  
Data show that T3cDM is commonly associated 
with chronic pancreatitis, with a prevalence from 25% 
to 80%. A significant risk factor is the duration of 
chronic pancreatitis, which also causes the onset of 
diabetes due to exhaustion of the pancreatic endocrine 
reserve (4, 5). 
 In the case of hereditary pancreatitis, the mean age 
of secondary pancreatitis diabetes is between 38-53 
years, and in the case of chronic pancreatitis for other 
causes, the onset age is less specific (6, 7). 
Over the past 20 years, significant efforts have been 
made both in deciphering the genetic mechanisms that 
can compete with chronic pancreatitis and in the study 
of risk factors and/or the progression of this disease (8). 
However, the link with T3cDM requires more 
systematic investigations to determine the genetic 
potential for differentiation between currently known 
diabetes, such as type 1 diabetes (T1DM), type 2 
diabetes mellitus (T2DM), and latent autoimmune 
diabetes of adulthood (LADA), etc. (9).     
From an immunological perspective, the 
association of T1DM with specific HLA alleles has not 
been demonstrated in secondary diabetes of chronic 
pancreatitis. This aspect was also able to support the fact 
that patients with chronic pancreatitis reach late (in the 
stages of disease evolution) absolute insulin, secondary 
diabetes being successfully treated with oral 
antidiabetics (10).  
A small proportion of patients with chronic 
pancreatitis and secondary diabetes develop a total 
deficiency of endogenous insulin secretion, but this does 
not completely alter the secretion of alpha cells, which 
is still minimally preserved. From a pathophysiological 
point of view, after an extended period of chronic 
pancreatitis evolution, the pancreas loses enough beta 
cells so that insulin secretion decreases to complete 
deficiency. The small mass of remaining cells no longer 
responds to glucose level diffusion perisinusoidal. 
Alterations in the enteroinsular axis also correlate with 
decreased secretory secretion levels, but diminishing 
secreted glucagon levels appear as a consequence of 
exocrine dysfunction of alpha cells. Glycemic 
contractility is not preserved, hypoglycemia does not 
stimulate glucagon secretion, and catecholamine 
secretion is maintained in secondary diabetes compared 
to T1DM. Hypoglycemia is more severe than in T1DM 
due to a lack of glucagon secretion stimulation and 
probably also due to associated liver disease, 
malnutrition, and alcoholism, all of which are often 
associated with chronic pancreatitis (11).  
Diagnosis of secondary diabetes by chronic 
pancreatitis is based on the determination of pancreatic 
C-peptide and apparently concomitantly with the 
glycemic profile or the oral glucose tolerance test 
(OGTT), along with the determination of glycosylated 
hemoglobin level (HbA1C%). At the onset of decline in 
endocrine function, HbA1C% or peptide C is not helpful 
as an assessment criterion.  
Determination of post-prandial glycaemia may 
provide real benefits in assessing the decline in beta cell 
function. For such situations, diet, alcohol withdrawal, 
and oral antidiabetics offer the main treatment options. 
Insulin therapy and basal-bolus enhancement are 
indicated for patients with good compliance, and a 7% 
HbA1C target is preferred (compared to 6.0%) to avoid 
hypoglycemia that may be extremely severe for these 
patients. In patients with pancreatogenic diabetes, 
ketoacidoses are rare events (12, 13).  
The secretion of the pancreatic polypeptide is 
absent in the secondary insulin-dependent pancreatitis 
due to pancreatic beta cell damage with exocrine 
damage. The plasma level of somatostatin secretion is 
increased in patients with insulin-requiring diabetes 
secondary to chronic pancreatitis (14, 15). 
Long-term complications in patients with diabetes 
secondary to chronic pancreatitis compared to those in 
T1DM are highly dependent on the duration of diabetes 
itself. Life expectancy is generally generally reduced 
especially if patients do not give up alcohol and tobacco 
(16).  
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Materials and Methods 
Two hundred and sixty-one patients, women and 
men with a chronic history of pancreatitis, who came to 
the medical visit for re-evaluation, were investigated. 
Other patients who did not have the diagnosis of 
pancreatogenic secondary diabetes but who had chronic 
pancreatitis were also investigated.  
Results 
Of the 216 patients diagnosed with chronic 
pancreatitis, only 59 (27.3%) cases developed secondary 
diabetes, documented prior to the visit. The patients 
were 22.2% women and 77.8% men, with average ages 
of 56.8 years and 53.4 respectively. 63% came from 
urban areas. 
The mean duration of chronic pancreatitis was six 
years. Non-diabetic patients were compared with 
patients who had previously been diagnosed with 
diabetes and who were analysed for body mass index 
(BMI). Biochemical data and imaging investigations 
were performed: abdominal ultrasound, computed 
tomography, and nuclear magnetic resonance (Tables 1, 
2). We used IBM SPSS 20.0 for statistical analysis Excel 
and Epi Info. 
Following the analysis of the batches,  
• diabetes patients had an average basal blood 
sugar of 133 mg / dL [25%, 75%] = [100, 178], the 
minimum value was 65 mg / dL, maximum: 396 mg / 
dL, 
• non-diabetic patients showed the following: 
minimum value is 94 mg / dL, maximum: 145 mg / dL, 
median: 119 mg / dL, 25% 75% = [105, 144],  
• normoponderal nondiabetics: the minimum 
value is 62 mg / dl, maximum: 243 mg / dl, median: 110 
mg / dl, [25%, 75%] = [95, 135.5] the lowest is 62 mg / 
dl, the maximum: 234 mg / dl, the median: 112.5 mg / 
dl, [25%, 75%] = 100, 154,  
• obese nondiabetics: / dl, median: 115 mg / dl, 
[25%, 75%] = [100, 147]). 
 
Figure 1. Basal blood glucose assessment. 
Basal blood glucose (a jeun) was 133 mg/ dl 
(normal <100 mg / dl) in the diabetic and non-diabetic 
groups with an average mean value between 110 and 
119 mg/ dl, which suggests that basal glycemia is 
already being altered in patients who have not been 
diagnosed with diabetes secondary to chronic 
pancreatitis. Patients diagnosed with secondary diabetes 
mellitus with chronic pancreatitis had a mean HbA1c% 
of 7.9 and peptide C of 0.7 ng / mL. Reference values 
for peptide C were 0.81-3.85 ng / mL. 
Non-diabetic patients also had altered glycemic 
values, requiring additional HbA1C% and C-peptide 
tests, possibly performing a glucose tolerance test 
(OGTT). The glycemic difference between the two 
groups, diabetic vs. non-diabetic, is explained by the fact 
that diabetic patients were already undergoing specific 
metformin and basal insulin therapy, and those in the 
second batch were found with glycemic values altered 
during the re-evaluation visit without having previously 
received extensive diabetic investigations or specific 
treatment. Differences between batches were significant 
(p = 0.0296 Kruskal-Wallis): Diabetics-Nondiabetic- 
normoponderal: p value = 0.010725. 
Determination of gamma-glutamyl transpeptidase 
(GGT) in: 
• diabetic patients show a minimum value is 19, 
maximum, 2513, median: 128, [25%, 75%] = [97,196]; 
• underweight nondiabetics: 308, median: 93.5, 
[25%, 75%] = [27, 136],  
• normoponderal nondiabetics: minimum value 
is 15, maximum: 973, median: 92, [25%, 75%] = [68.5,  
• overweight: the minimum is 23, maximum: 
932, median: 96, [25%, 75%] = [27, 99.5] and obese 
nondiabetic patients: = [77,115].  
Comparing the values between batches, significant 
differences are obtained (0.0000 Kruskall-Wallis): 
Diabetic-Nondiabetic normoponderal: p value = 
0.000072 and Diabetic-Nondiabetic overweight: p value 
= 0.000469 (Figure 2). 
GGT catalysis the transfer of the γ-glutamyl group 
from peptides such as glutathione (GSH) to other amino 
acids. The increase in serum GGT is also due to cell 
membrane damage by toxins (including alcohol), 
ischemia, infections, or cell membrane disruption of the 
enzyme as a result of bile acid action. GGT is an enzyme 
specific to the liver and bile ducts. Normal levels in 
women are <36 U / L and in men <61 U / L. 
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Imaging investigations, especially routine 
abdominal ultrasound, revealed an incidence of tumours 
and pseudotumors in diabetic patients 12/59 (20.3%), 
underweight nondiabetics 1/10 (10.00%), normal 
nondiabetic 7/84 (8.3%), overweight overdose 1/36 
(2.8%), and obese nondiabetics 1/27 (3.7%). 
CT scan confirmed these data. Tumour density at 
the pancreatic level was the highest in the diabetic 
group, 20.3%, reiterating the hypothesis that the 
incidence is higher compared to non-diabetic patients, as 
previous research has shown. 
By comparing the percentages between diabetics 
(20.3%) and overweight nondiabetics (2.8%), p = 
0.06354, marginally statistically significant (Figure 3). 
 
Figure 3. Abdominal ultrasonographic evaluation. 
 
 
Figure 4. Evaluating ethanol consumption. 
Consumption of ethanol for diabetic patients was 
52.5% compared to non-diabetic patients 41,4%. 
Chronic ethanol consumption is not only a risk factor 
that worsens chronic pancreatitis but is also a known risk 
factor for chronic liver disease. Chronic pancreatic and 
hepatic injury can lead to the installation of caloric 
protein malnutrition. Underweight patients with chronic 
pancreatitis should therefore also be investigated from a 
nutritional perspective, malnutrition further negatively 
affects the prognosis. 
The association between alcohol consumption and 
sex in the whole sample showed that the proportion of 
alcohol-consuming women (27.1%) differed 
significantly from the percentage of men consuming 
alcohol (70.2%) (p = 0.000001 Chi-square). Smoker 
status was described in 18.8% of women and 62.5% of 
men (p = 0.000001 Chi-square) (Figure 4). 
  
Figure 2. GGT assessment by batches. 
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Table 1. Biochemical analyses 
 Diabetic 
Nondiabetic 
Underweight 
Nondiabetic 
Normal 
weight 
Nondiabetic 
Overweight 
Nondiabetic 
Obese 
p_value 
(test) 
N 59 (27.3%) 10 (4.6%) 84 (38.9%) 36 (16.7%) 27 (12.5%) 
 
HEMOGLOBIN 13.14-1.5332 12.99- 1.6224 13.43- 1.6989 13.08- 2.0702 13.58- 1.7126 0.6247 (ANOVA) 
LEUKOCYTE 
7500 
[5800, 9910] 
8015 
[7500,12610] 
7459 
[6265, 8995] 
7550 
[6585, 8545] 
7250 
[6000, 9500] 
0.5824  
(Kruskall-Wallis) 
PLATELETS 
259640.6-
98243 
274000.0-
115434 
269852.3-
116441 
257916.6-
112707 
259000.0-
83290 
0.9619  
(ANOVA) 
CALCIUM 
8.20 
[3.01, 44.50] 
9.45 
[1.20, 23.00] 
7.84 
[3.02, 18.45] 
8.52 
[3.50, 15.05] 
4.30 
[2.05, 12.70] 
0.5527  
(Kruskall-Wallis) 
FIBRINOGEN 
404.0 
[342.0, 501.0] 
440.0 
[257.0, 624.0] 
384.2 
[317.5, 476.5] 
427.5 
[364.0, 464.0] 
385.0 
[319.0, 487.0] 
0.7648  
(Kruskall-Wallis) 
AST 
36.0 
[26.0, 62.0] 
28.5 
[17.0, 36.0] 
31.0 
[23.0, 59,5] 
43.0 
[26.0, 65.0] 
40.0 
[26.0, 62.0] 
0.1199  
(Kruskall-Wallis) 
ALT 
33.0 
[20.0, 59.0] 
31.0 
[19.0, 34.0] 
33.0 
[22.0, 47.0] 
32.0 
[25.0, 50.5] 
33.0 
[22.0, 57.0] 
0.7407  
(Kruskall-Wallis) 
TOTAL BILIRU-
BIN 
36.0 
[0.70, 83.00] 
0.61 
[0.40, 55.00] 
27.0 
[0.60, 74.00] 
37.0 
[0.60, 71.50] 
41.0 
[0.90, 99.00] 
0.6031  
(Kruskall-Wallis) 
GGT 
128.0 
[97, 196] 
93.5 
[27, 136] 
92 
[68.5, 103] 
86.5 
[72, 99.5] 
96 
[77, 115] 
0.0000  
(Kruskall-Wallis) 
GLUCOSE 
133 
[100, 178] 
119 
[105, 144] 
110 
[95, 135] 
112.5 
[100, 154] 
115 
[100, 147] 
0.0296  
(Kruskall-Wallis) 
LIPASE 
143 
[91, 243] 
232 
[123, 300] 
133 
[95.5, 234] 
144 
[87, 267] 
145 
[95, 296] 
0.5228  
(Kruskall-Wallis) 
AMYLASE 
100 
[71, 145] 
111.5 
[55, 134] 
100 
[65, 161] 
104.5 
[56.5, 156] 
85 
[65, 156] 
0.9953  
(Kruskall-Wallis) 
Table 2. Imaging evaluations  
 Diabetic 
Nondiabetic 
Underweight 
Nondiabetic 
Normal 
weight 
Nondiabetic 
Overweight 
Nondiabetic 
Obese  
p_value 
(test) 
Number 59 (27.3%) 10 (4.6%) 84 (38.9%) 36 (16.7%) 27 (12.5%)  
PANCREATIC Eco 
CALCIFICATIONS 
33/59 (55.9%) 9/10 (90.0%) 50/84 (59.5%) 23/36 (63.9%) 14/27 (51.9%) 
0.2752  
(Chi-square) 
PANCREATIC Eco 
STRUCTURE 
Hyperechoic 
Hyperechoic + 
Heterogeneous 
Hypoechogenyc 
Hypoechogenyc + 
Heterogeneous 
Heterogeneous 
Normoechogen 
 
 
4/59 (6.8%) 
3/59 (5.1%) 
 
2/59 (3.4%) 
0/59 (0%) 
 
47/59 (79.7%) 
3/59 (5.1%) 
 
 
0/10 (0%) 
5/10 (50.0%) 
 
0/10 (0%) 
0/10 (0%) 
 
5/10 (50.0%) 
0/10 (0%) 
 
 
3/84 (3.6%) 
11/84 (13.1%) 
 
1/84 (1.2%) 
1/84 (1.2%) 
 
59/84 (70.2%) 
9/84 (10.7%) 
 
 
2/36 (5.6%) 
3/36 (8.3%) 
 
0/36 (0%) 
0/36 (0%) 
 
26/36 (72.2%) 
5/36 (13.9%) 
 
 
2/27 (7.4%) 
6/27 (22.2%) 
 
0 (0%) 
0 (0%) 
 
18/27 (66.7%) 
1/27 (5.6%) 
 
 
0.183328 
(Likelihood Raţio) 
Eco PANCREATIC 
pseudocyst 
20/59 (33.9%) 3/10 (30.0%) 27/84 (32.1%) 19/36 (52.8%) 13/27 (48.1%) 
0.175480 
(Likelihood Raţio) 
Eco_PSEUDO-
TUMOR 
12/59 (20.3%) 1/10 (10.0%) 7/84 (8.3%) 1/36 (2.8%) 1/27 (3.7%) 
0.037122 
(Likelihood Raţio) 
Eco_LIPOMA-
THOSIS 
13/59 (22.0%) 3/10 (30.0%) 22/84 (26.2%) 11/36 (30.6%) 8/27 (29.6%) 
0.891107 
(Likelihood Raţio) 
Eco_DIMENSIONS 
Atrophyc 
Hypertrophic 
Hypotrophic 
Normal 
 
3/59 (5.1%) 
29/59 (49.2%) 
7/59 (11.9%) 
20/59 (33.9%) 
 
0/10 (0%) 
5/10 (50.0%) 
2/10 (20.0%) 
3/10 (30.0%) 
 
1/84 (1.2%) 
40/84 (47.6%) 
8/84 (9.5%) 
35/84 (41.7%) 
 
0/36 (0%) 
20/36 (55.5%) 
2/36 (5.6%) 
14/36 (38.9%) 
 
1/27 (3.7%) 
17/27 (63.0%) 
1/27 (3.7%) 
8/27 (29.6%) 
 
0.636408 
(Likelihood Raţio) 
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Discussions 
Compared to type I DM, T3cDM shows many 
different properties: glycemic lability, more frequent 
hypoglycemic episodes, and minimum incidence of 
ketoacidosis. The need for insulin administration to 
achieve satisfying diabetes mellitus compensation is 
significantly lower and response of peripheral tissues to 
endogenous and exogenous insulin substantially higher 
compared to type I diabetics. These clinical differences 
result from decreased but always preserved insulin 
secretion, decreased glucagon production, impaired 
external pancreatic secretion, excessive alcohol or 
tobacco use, or insufficient or irregular food intake. 
Secondary DM in chronic pancreatitis is accompanied 
by chronic, microangiopathic, and neuropathic 
complications analogous to other DM types (16). 
Diabetes secondary to pancreatic involvement was 
initially described and referred to as pancreatogenic 
diabetes. The type IIIC diabetes nomenclature was first 
proposed in 2014 by the American Diabetes 
Association, with the name type 3c diabetes now 
commonly accepted (17-19). The most widely reported 
conditions are the presence of chronic pancreatitis 
(79%), pancreatic ductal adenocarcinomas (8%), 
haemochromatosis (7%), cystic fibrosis (4%), and 
previous pancreatic surgery (2%) (20-22). 
As diagnostic criteria, Ewald and Brezel proposed 
3 major criteria: documentation of exocrine pancreatic 
insufficiency (abnormalities of the pancreas), 
documented imagistic (ultrasound, CT or MRI), and 
absence of markers for T1DM 1 (23). Minor criteria 
involve documenting cellular dysfunction (pancreatic 
peptide C assay, glycemic profile), insulin resistance, 
 Diabetic 
Nondiabetic 
Underweight 
Nondiabetic 
Normal 
weight 
Nondiabetic 
Overweight 
Nondiabetic 
Obese 
p_value 
(test) 
Number 59 (27.3%) 10 (4.6%) 84 (38.9%) 36 (16.7%) 27 (12.5%)  
CT_RMN_SPLENO
MEGALY 
0 (0%) 0/10 (0%) 2/84 (2.4%) 2/36 (5.6%) 0/27 (0%) 
0.240927 
(Likelihood Raţio) 
CT_RMN 
LOCATION 
Caudal 
Cephalic 
Cephalic-caudal 
Cephalic-corporeal 
Tail 
Body 
Corporeal 
Corporeo-caudal 
Without 
 
2/59 (3.4%) 
15/59 (25.4%) 
0/59 (0%) 
1/59 (1.7%) 
1/59 (1.7%) 
2/59 (3.4%) 
2/59 (3.4%) 
3/59 (5.1%) 
33/59 (55.9%) 
 
0/10 (0%) 
2/10 (20.0%) 
0/10 (0%) 
2/10 (20.0%) 
0/10 (0%) 
0/10 (0%) 
0/10 (0%) 
0/10 (0%) 
6/10 (60.0%) 
 
4/84 (4.8%) 
17/84 (20.2%) 
0/84 (0%) 
4/84 (4.8%) 
0/84 (0%) 
0/84 (0%) 
3/84 (3.6%) 
4/84 (4.8%) 
52/84 (61.9%) 
 
0/36 (0%) 
9/36 (25.0% 
1/36 (2.8%) 
3/36 (8.3%) 
2/36 (5.6%) 
0/36 (0%) 
3/36 (8.3%) 
1/36 (2.8%) 
17/36 (47.2%) 
 
2/27 (7.4%) 
5/27 (18.5%) 
0/27 (0%) 
4/27 (14.8%) 
0/27 (0%) 
0/27 (0%) 
2/27 (7.4%) 
1/27 (3.4%) 
13/27 (48.1%) 
 
0,439811 
(Likelihood Raţio) 
CT_RMN_ 
NEIGHBORHOOD 
STRUCTURES 
REPORT 
Coledoc 
Duodenum 
Liver 
Spleen 
Stomach 
Without 
 
 
 
 
3/59 (5.1%) 
7/59 (11.9%) 
0/59 (0%) 
5/59 (8.5%) 
3/59 (5.1%) 
41/59 (69.5%) 
 
 
 
 
2/10 (20.0%) 
1/10 (10.0%) 
1/10 (10.0%) 
0/10 (0%) 
0/10 (0%) 
6/10 (60.0%) 
 
 
 
 
5/84 (6.0%) 
7/84 (8.3%) 
2/84 (2.4%) 
4/84 (4.8%) 
1/84 (1.2%) 
65/84 (77.4%) 
 
 
 
 
5/36 (13.9%) 
3/36 (8.3%) 
0/36 (0%) 
4/36 (11.1%) 
4/36 (11.1%) 
20/36 (55.6%) 
 
 
 
 
5/27 (18.5%) 
3/27 (11.1%) 
1/27 (3.7%) 
1/27 (3.7%) 
2/27 (7.4%) 
15/27 (55.6%) 
 
0.193701 
(Likelihood Raţio) 
PERIPHANTICAL 
COLLECTIONS 
6/59 (10.2%) 2/10 (20.0%) 12/84 (14.3%) 5/36 (13.9%) 1/27 (3.7%) 
0.468933 
(Likelihood Raţio) 
CALCIFICATIONS 39/59 (66.1%) 7/10 (70.0%) 50/84 (59.5%) 28/36 (77.8%) 16/27 (59.3%) 
0.355862 
(Likelihood Raţio) 
EDS_HTPO 5/59 (8.5%) 1/10 (10.0%) 3/84 (3.6%) 0/36 (0%) 1/27 (3.7%) 
0.214733 
(Likelihood Raţio) 
EDS_ 
GASTRITIS 
ESOPHAGITIS 
DUODENITIS 
WITHOUT 
 
11/59 (18.6%) 
10/59 (16.9%) 
12/59 (20.3%) 
26/59 (44.1%) 
 
1/10 (10.0%) 
2/10 (20.0%) 
1/10 (10.0%) 
6/10 (60.0%) 
 
11/84 (13.1%) 
16/84 (19.0%) 
14/84 (16.7%) 
43/84 (51.2%) 
 
8/36 (22.2%) 
4/36 (11.1%) 
5/36 (13.9%) 
19/39 (52.8%) 
 
5/27 (18.5%) 
3/27 (11.1%) 
8/27 (29.6%) 
11/84 (40.7%) 
0.840650 
(Likelihood Raţio) 
EDS_ULCER 7/59 (11.9%) 0/10 (0%) 5/84 (6.0%) 5/36 (13.9%) 3/27 (11.1%) 
0.338545 
(Likelihood Raţio) 
HGTH 6/59 (10.2%) 4/10 (40.0%) 21/84 (25.0%) 7/36 (19.4%) 4/27 (14.8%) 
0.0930 (Chi-
square) 
ESOPHAGEAL 
VARICOSE VEINS 
5/59 (8.5%) 1/10 (10.0%) 3/84 (3.6%) 1/36 (2.8%) 1/27 (3.7%) 
0.625388 
(Likelihood Raţio) 
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alteration of secretory secretion (glucagon-like peptide-
1 [GLP-1] and/ or pancreatic polypeptides), and 
evaluation of liposoluble vitamin deficiency (A, D, E, 
K). Although the duration of chronic pancreatitis 
somewhat influences these criteria, the clear 
differentiation between T1DM, T2DM and 
pancreatogenic type 3C diabetes shows an imprecise 
standardization of β-cell dysfunction and insulin 
resistance. The lack of the concrete data on glucose 
homeostasis in T3cDM makes some interpretations 
difficult, so there are still many limitations in this regard, 
namely there are still no precise data that can standardize 
both diagnosis and therapeutic options (and that is why 
more studies would be necessary. However, with the 
little information available thus far, we can conclude 
that T3cDM is an important pathological entity, most of 
the time underestimated and clinically ignored, initially 
treated as a T2DM that evolves into insulin-deficiency, 
specific to T1DM. Consistent with other studies, it is 
essential to create management strategies for T3cDM, 
which must include therapeutic options for improving 
intestinal absorption, assessing nutritional status, and 
minimizing malnutrition. As our study has shown, a 
small percentage of patients with chronic pancreatitis 
(27.3%) developed T3cDM, the rest requiring 
investigations to confirm or nullify the diagnosis. The 
non-diabetic patients, who had changed basal blood 
glucose values, were mostly overweight and obese, and 
therefore cannot be ruled out in this context of insulin 
resistance. This situation should be investigated by 
laboratory tests (peptide C determination, OGTT test) 
which for objective reasons could not be achieved in this 
study. Patients predisposed to T3cDM are mostly men 
with a history of chronic alcohol and tobacco use, again, 
consistent with other research studies. Imaging 
evaluations have detected some abnormalities of the 
pancreas, from various degrees of a tumour or 
pseudotumor to more complicated clinical situations 
requiring surgery and even pancreatectomy (24). While 
any patient with chronic pancreatitis should be 
monitored for the development of diabetes, those with 
long-standing duration of the disease, prior partial 
pancreatectomy, and early onset of calcific disease may 
be at higher risk. Those patients developing DM are 
likely to have co-existing pancreatic exocrine 
insufficiency. The treatment administered on one hand, 
and the enzymatic insufficiency instituted following 
chronic pancreatitis on the other hand, contribute to the 
disease expression and evolution (21). The major risks 
in all these circumstances are those of severe 
hypoglycemia characteristic of T3cDM. Optimization of 
lifestyle, nutritional intervention, and education of the 
patient with T3cDM did not differ from that of patients 
with type 2 diabetes (22, 23).  
The major drawback of our study is that we initially 
intended to assess the evolution of chronic pancreatitis 
and glycemic values in patients previously diagnosed 
with pancreatogenic diabetes mellitus. However, we 
were unable to continue observations on non-diabetic 
patients, although they were detected in the course of the 
hospital visit through basal blood glucose changes. A 
second limitation stemmed from lack of availability of 
patients, access to more complex determinations in the 
diagnosis of pancreatic T3cDM diabetes, and the 
assessment of glycemic variability utilizing modern 
monitoring devices (continuous blood glucose 
monitoring systems).  
Conclusions 
In light of prior research, together with our results, 
we can conclude that T3cDM is a new pathological 
entity that needs to be explored more deeply to lead to 
improved diagnosis and therapeutic stability. More 
studies are needed in this regard, from both 
epidemiological and pathophysiological perspectives, as 
no conclusive data exist in present regarding the 
population and pathophysiological incidence (due to the 
fact that the exact mechanisms of onset of T3cDM are 
not fully known).  
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